News

The new facility will provide the additional space needed for Impact Analytical as well as safe, efficient and accurate analysis of customer samples. Impact Analytical business manager Eric

OMS824 was well tolerated in the SAD study in which expected pharmacological effects were established in healthy subjects. The trial was designed to assess the multiple-dose administration of

Under the collaboration, Lilly will in-license a portfolio of branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab based in Bangalore,

The annual general meeting held on 17 October 2012, has approved the acquisition of 100% of the shares of X-Pol by way of a capital increase against contribution

The drug developed by Sol-Gel, is used to treat mild-to-severe rosacea as well as acne. The study demonstrated that 5% E-BPO provides a safe and effective treatment for

I-Accountability decreases workload at the site by centralising and automating the drug accountability process as well as improving compliance and advancing study timelines. The system also features QR

According to the clinical development agreement, Protalix will continue to manage and fund Elelyso (taliglucerase alfa) ongoing trials while the new studies of the enzyme replacement therapy will

The companies are also considering signing a licensing contract to develop new DuoBody product. Genmab’s DuoBody platform swiftly generates bispecific antibodies through a process performed at standard bench,

The collaboration will make use of Amorfix’s ProMIS discovery technology and the terms of the deal are kept confidential. Amorfix president and CEO Dr. Robert Gundel said, "This